Genesis Care Pty Limited and 52 affiliates filed chapter 11 on June 1, 2023 in the U.S. Bankruptcy Court for the Southern District of Texas, lead case number 23-90614 before Hon. David R. Jones. The Australian-headquartered global oncology operator entered the case with approximately $1.7 billion of funded debt, an $800 million super-priority DIP commitment from its prepetition term lenders, and a dual-track strategy: a Section 363 sale of its U.S. business and a reorganization of the Australian, U.K., and Spanish operations as "Reorganized ROW TopCo."
The filing was driven by a failed integration of 21st Century Oncology, sustained losses in the U.S. business, and a refusal by four of the thirteen RCF banks to fund a draw the company maintained it was entitled to make. Judge Jones confirmed the First Amended Joint Plan on November 22, 2023, and the plan went effective February 16, 2024, cancelling existing TopCo equity, distributing new warrants and cash to senior facility lenders, and leaving U.S. unsecured creditors with no recovery. Reorganized-debtor litigation against multiple sale buyers continued through 2025.
Genesis Care Pty Limited (53 jointly administered entities)
Court
U.S. Bankruptcy Court, Southern District of Texas (Houston Division)
Case Number
23-90614
Petition Date
June 1, 2023
Confirmation Date
November 22, 2023
Effective Date
February 16, 2024
Judge
Hon. David R. Jones
DIP Facility
$800 million super-priority term loan from Ad Hoc Term Lender Group ($200M new money / $600M roll-up)
Funded Debt at Filing
Approximately $1.7 billion
Claims Agent
Kroll Restructuring Administration LLC
Case Snapshot
From KKR Buyout to a Dual-Track Cross-Border Filing
GenesisCare was launched by Dan and Dr. Geoff Holt in partnership with the cardiologists of HeartCare Partners, with DCA Partners as a cornerstone investor. KKR first acquired roughly 45% of the company in 2012, sold its position in 2016 to China Resources Capital — which retained a ~35% stake at filing — and reinvested in October 2018 to take back approximately 30%. Management and physicians held the remaining equity. Alan Carr served as a KKR-designated independent director on the TopCo board through the restructuring.
By the petition date, GenesisCare operated 40 oncology centers in Australia, 14 radiation oncology centers in the U.K., 21 centers in Spain, and 280 U.S. locations across the "GC US" business, and employed more than 5,500 healthcare professionals globally. The company described itself as the world's largest provider of radiotherapy and the largest U.S. employer of urologists. The U.S. footprint was anchored by the May 2020 acquisition of 21st Century Oncology, a network of physician-led cancer treatment centers structured under two operating models: a Company-Owned Business Model with directly employed physicians and a Services Agreement Business Model providing administrative and management services to physician-owned facilities.
Failed 21C Integration and the Defaulting Banks Liquidity Trigger
The First Day Declaration of CEO David Young identified five overlapping causes of distress, with the first three concentrated on U.S. performance after the 21C acquisition. The 21C integration produced declining revenue cycle management, antiquated IT systems, and aged equipment alongside failed synergies, leaving GC US chronically unprofitable and dependent on cash flow from the Rest of World operations. A second 21C-specific issue compounded the integration failure: because 21C had employed physicians in counties without competing same-specialty practices, non-compete agreements were voided after the acquisition, allowing former 21C-affiliated doctors to open competing centers near GC US locations and recruit the highest-billing physicians, particularly in West Florida.
Beyond the U.S. business, GenesisCare invested in global initiatives that increased overhead without a clear path to positive cash flow. The company concluded by 2023 that it lacked the capital to fund a U.S. turnaround on its own and that a sale of the U.S. business was in the best interest of stakeholders.
The proximate trigger was a lender default. In April 2023, four of the thirteen banks in the company's Revolving Credit Facilities (the "Defaulting Banks") refused to fund draw-down requests for approximately AUD $76 million the company maintained it was entitled to draw. GenesisCare ultimately received only AUD $44 million, accelerating a liquidity crisis that drove the chapter 11 filing weeks later. The Official Committee of Unsecured Creditors subsequently disclosed it was investigating $2.5 million in prepetition retention payments to two top executives made shortly before the filing, alongside the 21C acquisition itself and other prepetition conduct of former directors and officers.
$1.7 Billion Capital Structure and KKR/APH Sponsor Loans
The Debtors entered chapter 11 with approximately $1.7 billion in total funded debt across four prepetition instruments. The senior tranche was a $1,547 million Term Loan B issued in two tranches with maturities in October 2025 and May 2027, secured by first-priority liens on substantially all assets of the guarantors. The TLB carried material exposure in European CLO portfolios, with the default treated as a credit event in the EMEA leveraged credit market. Ranking pari passu with the TLB on shared collateral was an $81 million outstanding balance under the Revolving Credit Facility (RCF1 and RCF2), drawn against an aggregate AUD $200 million commitment. Kroll Agency Services Limited served as facility agent for the Senior Facilities Agreement, and Kroll Trustee Services Limited (formerly Lucid Trustee Services Limited) served as security trustee.
Two sponsor-related loans sat outside the senior facility. The $56 million KKR Loan, originally an AUD $75 million June 2022 emergency loan from a KKR-managed fund to address a prior liquidity shortfall, carried a first lien on substantially all property of TopCo and accrued PIK interest with a maturity extendable to May 30, 2024. A $31 million APH Loan, secured by a second lien on TopCo property and similarly PIK-bearing, had a maturity extendable to January 31, 2024. Both loans were structurally junior to the Senior Facilities Agreement on guarantor collateral but had recourse to TopCo equity value.
The capital structure produced the case's central recovery dynamic: senior facility lenders were undersecured at filing, while the sponsor-related loans relied on equity that the plan ultimately cancelled.
$800 Million DIP Facility and 3:1 Roll-Up Ratio
The Debtors obtained an $800 million super-priority DIP facility from an Ad Hoc Term Lender Group of consenting Senior Facilities Agreement lenders, the "Backstop Parties." The facility carried a 3:1 roll-up to new money ratio: $200 million in new money (a $90 million Initial Term Loan plus $110 million in Delayed Draw Term Loans) against $600 million in roll-ups ($270 million Interim Roll-Up and $330 million Final Roll-Up). The structure converted prepetition senior lender claims to DIP claims at scale and effectively eliminated any meaningful competing DIP alternative.
DIP pricing on the new money tranche was SOFR plus 10.00% per annum (with a 1.00% SOFR floor and customary credit spread adjustments), with 1.50% payable in cash and the remainder PIK. Roll-Up DIP Loans accrued at the non-default rate under the prepetition Senior Facilities Agreement, again with 1.50% cash and the remainder PIK. The Closing Fee was 3.00% of aggregate new money principal (PIK), the Ticking Fee was 0.75% per annum on unfunded new money commitments (PIK), and the Exit Fee was 3.00% of actually funded new money (cash if the Debtors elected repayment).
The DIP matured on the earliest of 364 days after closing, 35 days after Interim Order entry if a Final Order was not entered, consummation of a Section 363 sale of substantially all assets (excluding the U.S. Business), the effective date of a confirmed plan, or acceleration on Event of Default. Adequate protection for prepetition secured parties consisted of Adequate Protection Liens, super-priority claims, and credit-bid rights in any 363 sale up to the full amount of their Adequate Protection Obligations, Prepetition Obligations, and DIP Obligations.
The case's U.S. track was structured as a Section 363 sale running on tight DIP-driven milestones. Measured from the Petition Date, the DIP imposed sale milestones running from data room access at 10 days through bidding procedures at 45 days, bid deadline at 110 days, auction commencement at 115 days, sale order entry at 125 days, and sale closing at 145 days. The Court entered the Bidding Procedures Order on July 19, 2023, setting a September 22, 2023 bid deadline and an October 4, 2023 auction date. Break-up fees and expense reimbursement were available only to a court-approved Stalking Horse Bidder, and the Debtors were authorized but not obligated to designate one. The auction date and related deadlines were extended at least twice through notices filed October 31 and November 7, 2023.
The sale process did not produce a single going-concern buyer for GC US. The Notice of Winning Bidders filed November 13, 2023 reported that multiple buyers had purchased discrete U.S. practices: Limitless Partners, LLC took three Alabama practices in Andalusia, Enterprise, and Dothan; City Hospital, Inc. doing business as Berkeley Medical Center acquired 60% equity in Ambergris, LLC; American Shared Hospital Services took 60% equity in Southern New England Regional Cancer Center, LLC and Roger Williams Radiation Therapy, LLC, plus certain commercial payor contracts; Greenbelt Radiation Center, LLC purchased one Maryland practice; and Oncology Consultants, PLLC acquired three Nevada practices and a Washington practice. The notice did not disclose an aggregate purchase price for the U.S. sale.
A separate transaction approved under the bidding procedures involved Reorganized Debtor U.S. Cancer Care, Inc. and MRKS, Inc. The parties signed an Investment Agreement on December 7, 2023 for the sale of 100% equity in GenesisCare USA Salinas Valley Memorial Radiation Therapy Management, LLC plus certain acquired contracts. The original purchase price was $3.6 million, subsequently amended to $2.4 million. Memorial Healthcare System — a South Florida hospital network operated by South Broward Hospital District — was among the entities that pursued but did not complete an acquisition of GenesisCare assets, as reflected in its January 2024 board meeting materials. A change-of-control transfer of GenesisCare USA, Inc.'s nuclear byproduct-materials license to Berkeley Medical Center was the subject of a December 21, 2023 NRC consent request, reflecting the regulatory complexity of moving radiation oncology practices between operators.
The sale process drew an objection from Atlantic Urologic Clinics physicians, who argued that prospective bidders were prevented from engaging with physicians about employment terms and that their personal-services employment agreements were not assignable without consent, putting deferred compensation at risk without administrative claim protection. The Debtors and "Doctor Parties" entered multiple stipulations regarding a motion to quash tied to ongoing physician disputes during the case. Bayer Consumer Care AG moved to terminate a clinical trial contract, citing delays caused by the auction process.
Reorganized ROW TopCo and the Class 5B Disparity
The First Amended Joint Chapter 11 Plan, filed November 6, 2023, paired the U.S. 363 sale with a reorganization of the Australian, U.K., and Spanish operations as "Reorganized ROW TopCo." Plan Class 3 — SFA Claims and Swap Claims — was the only impaired voting class. Holders received pro rata shares of New Warrants for 10% of the reorganized equity and Distributable Cash under a waterfall recovery, against undersecured prepetition claims. Class 4 Shareholder Loan Claims (the KKR and APH sponsor loans) were impaired and deemed to reject, receiving no distribution. Class 5A General Unsecured Claims at the ROW Debtors were unimpaired and either reinstated or paid in full. Class 5B General Unsecured Claims at the GC U.S. Debtors were impaired and deemed to reject, with no distribution. Class 8A and 8B existing equity interests in TopCo and U.S. TopCo were impaired and deemed to reject, with no value to holders.
Class
Description
Status
Treatment
Class 1
Other Secured Claims
Unimpaired
Payment in full, reinstatement, or other unimpaired treatment
Class 2
Other Priority Claims
Unimpaired
Payment in full, reinstatement, or other unimpaired treatment
Class 3
SFA Claims and Swap Claims
Impaired (Voting)
Pro rata share of New Warrants and Distributable Cash per Waterfall Recovery
Class 4
Shareholder Loan Claims (KKR / APH)
Impaired (Deemed Reject)
Discharged; no distribution
Class 5A
GUCs (ROW Debtors)
Unimpaired
Reinstated or paid in full
Class 5B
GUCs (GC U.S. Debtors)
Impaired (Deemed Reject)
Discharged; no distribution
Class 6
Intercompany Claims
Per RTM
Per Restructuring Transactions Memorandum
Class 7A/7B
Intercompany Interests
Per RTM
Per Restructuring Transactions Memorandum
Class 8A
Existing TopCo Interests
Impaired (Deemed Reject)
Transferred, cancelled, or combination; no recovery
Class 8B
Existing U.S. TopCo Interests
Impaired (Deemed Reject)
Cancelled (US Equitization) or per RTM (Sale)
Class 9
Section 510(b) Claims
Impaired (Deemed Reject)
The Official Committee of Unsecured Creditors objected to the disclosure statement on three principal grounds: a premature timeline that left the U.S. sale results and ongoing investigations unresolved at solicitation; disparate creditor treatment, with no recovery for U.S. unsecured creditors (Class 5B) while ROW unsecured creditors (Class 5A) were unimpaired; and overbroad releases under which U.S. unsecured creditors granted broad third-party releases to directors, officers, equity holders, and lenders without reciprocal releases or any distribution. The Committee also raised the equity-flow point that undersecured Class 3 SFA Claim holders received warrants on 10% of reorganized equity while Class 5B received nothing, and disclosed open investigations into the 21C acquisition and prepetition retention payments. The plan was confirmed substantially as filed.
A separate Proskauer Rose-led ad hoc group response from holders of approximately 10% of the DIP loans and 10% of prepetition SFA loans expressed interest in participating in exit capital on a pro rata basis with the Required Lenders, while arguing that the original disclosure statement lacked the Rights Offering documentation and New Money Exit Facility terms needed to evaluate the plan. Three individual creditors — Robert Grapin, Valerie & Pieter Mare, and Greg Dunning — filed plan objections, with the Mares filing a competing plan and a separate stay-relief motion that was later withdrawn.
Confirmation was projected to reduce funded debt by $1.5 billion, and the confirmation order was entered November 22, 2023. The plan's debtor releases, third-party releases, exculpation provisions, and supporting injunction were detailed in the Brief in Support of Plan Confirmation. The Plan Effective Date arrived on February 16, 2024, approximately 260 days after the petition date, with confirmation itself reached in roughly 174 days from filing.
Estate Professionals, Critical Vendor Relief, and Patient Care Oversight
The estate professional roster reflected the case's cross-border architecture. Kirkland & Ellis LLP and K&E International served as lead restructuring counsel and requested $11,118,552 in fees plus $108,934 in expenses for the June 1 to August 31, 2023 first interim period. Alvarez & Marsal North America, LLC served as financial advisor at hourly rates of $425 to $1,375 with a $250,000 retainer. PJT Partners LP served as investment banker under a $175,000 monthly advisory fee, an $11 million restructuring fee, or a 1.50% transaction fee. Jackson Walker LLP served as Texas co-counsel, while Herbert Smith Freehills appeared as special foreign counsel for Australia and Clayton UTZ as special investigation counsel. Kobre & Kim LLP, retained as special counsel for Genesis Care Finance Pty Limited, requested $2,482,046 in fees plus $2,237 in expenses for the same first interim period.
MRKS Post-Emergence Dispute and Reorganized Debtor Litigation
The Reorganized Debtors continued to pursue claims against U.S. sale buyers well after the Effective Date. The most active dispute involved MRKS, Inc. The Reorganized Debtors filed a motion to enforce the Investment Agreement on November 5, 2024, seeking approximately $222,603 in unpaid post-closing amounts ($151,482.96 past due plus $71,121.05 in overpayment reimbursement). Judge Jones entered a Show Cause Order on January 22, 2025 regarding MRKS's noncompliance, and the parties held hearings between July 30 and October 29, 2025. The dispute settled on November 19, 2025 under a Stipulation and Agreed Order requiring MRKS to pay $70,000 to the Reorganized Debtors with the remaining $148,558.52 escrow balance returned to MRKS. Earlier in January 2024, a Texas judge had ordered compliance with the chapter 11 plan against a separate shareholder the company alleged was obstructing emergence.
The Reorganized Debtors also pursued the IROC (Interventional Radiation Oncology of California) sale buyer through a closing-related stipulation entered as the transaction wrapped on January 31, 2024. Post-confirmation, the estate filed omnibus claims objections under court-approved procedures entered in 2024, with at least two omnibus objections processed through 2024 and 2025 as the claims register was reconciled.
The following milestones track the case from GenesisCare's June 2023 petitions through plan effectiveness and post-emergence disputes.
Date
Event
2012
KKR initial investment in GenesisCare (~45%)
2016
KKR sells; China Resources Capital acquires ~35%
October 2018
KKR reinvests to ~30% stake
May 2020
Acquisition of 21st Century Oncology
June 2022
AUD $75M emergency loan from KKR-managed fund
April 2023
Defaulting Banks refuse AUD $76M RCF draw
June 1, 2023
Chapter 11 petitions filed for 53 entities (lead 23-90614)
June 2, 2023
Interim DIP Order entered
June 15, 2023
Official Committee of Unsecured Creditors appointed
July 7, 2023
Susan N. Goodman appointed patient care ombudsman
July 19, 2023
Final DIP Order and Bidding Procedures Order entered
September 8, 2023
Original Plan and Disclosure Statement filed
October 2, 2023
Order Conditionally Approving Disclosure Statement entered
November 6, 2023
First Amended Plan and supporting brief filed
November 13, 2023
Notice of Winning Bidders for U.S. assets filed
November 22, 2023
Confirmation Order entered
December 7, 2023
U.S. Cancer Care / MRKS Investment Agreement signed
Frequently Asked Questions
Who is the claims agent for GenesisCare?
Kroll Restructuring Administration LLC serves as the claims and noticing agent. The firm maintains the official claims register and distributes case notifications to creditors and parties in interest.
What was the size of the GenesisCare DIP facility?
The Court authorized an $800 million super-priority, multiple-draw term loan DIP facility from an Ad Hoc Term Lender Group, structured as $200 million in new money and $600 million in roll-ups of prepetition Senior Facilities Agreement obligations. The Court later approved an additional $20 million in DIP funding over a lender objection.
Did U.S. unsecured creditors recover anything under the plan?
No. Class 5B General Unsecured Claims at the GC U.S. Debtors were impaired and deemed to reject, receiving no distribution. ROW general unsecured claims (Class 5A) were unimpaired. Senior Facilities Agreement and Swap Claim holders (Class 3) received pro rata shares of New Warrants for 10% of reorganized equity and Distributable Cash under the waterfall.
Was the U.S. business sold to a single buyer?
No. The November 13, 2023 Notice of Winning Bidders identified multiple buyers for discrete U.S. practices, including Limitless Partners (Alabama), Berkeley Medical Center (Ambergris equity), American Shared Hospital Services (Southern New England and Roger Williams equity), Greenbelt Radiation Center (Maryland), and Oncology Consultants (Nevada and Washington). MRKS, Inc. separately purchased the Salinas Valley entity for $2.4 million.
omnibus claims objections under court-approved procedures /documents/81600e89-0931-49a4-8b43-f8360d90844d/
filed chapter 11 on June 1, 2023 https://www.bloomberg.com/news/articles/2023-06-01/genesiscare-may-split-off-us-assets-as-it-files-for-chapter-11
Judge Jones confirmed the First Amended Joint Plan https://www.law360.com/articles/1769315/genesiscare-gets-ok-for-ch-11-plan-to-slash-1-5b-in-debt
another KKR-backed health care chapter 11 https://www.law360.com/articles/1683515/another-kkr-backed-health-care-co-files-for-ch-11
characterized as a chapter 22 https://www.petition11.com/p/genesis-care
material exposure in European CLO portfolios https://www.trepp.com/trepptalk/european-market-update-clo-stability-default-downgrades-uk-logistics-sector
an additional $20 million in DIP funding https://www.law360.com/articles/1774242/genesiscare-gets-ok-for-20m-dip-funding-hike
was among the entities that pursued but did not complete an acquisition https://www.mhs.net/-/media/mhs/files/about-us/board-of-commissioners-meeting-agendas/2024/012424-binder-for-website.pdf
December 21, 2023 NRC consent request https://www.nrc.gov/docs/ML2400/ML24004A036.pdf
terminate a clinical trial contract https://news.bloomberglaw.com/bankruptcy-law/bayer-unit-says-genesiscare-bankruptcy-delayed-cancer-drug-tests
$84.9 million in prepetition critical vendor and patient care claims https://bankruptcy-proxy-api.dowjones.ai/cases/Texas_Southern_Bankruptcy_Court/4--23-bk-90614/Genesis_Care_Pty_Limited/docs/7.pdf
a Texas judge had ordered compliance https://www.law360.co.uk/articles/1786171/texas-judge-orders-compliance-with-genesiscare-s-ch-11
Fitch's 2024 healthcare bankruptcy enterprise-value case studies https://www.fitchratings.com/research/corporate-finance/healthcare-food-beverage-consumer-bankruptcy-enterprise-values-creditor-recoveries-2024-fitch-case-studies-01-11-2024
Fitch's June 2023 default-and-CLO commentary https://www.fitchratings.com/research/structured-finance/sizeable-defaults-limited-clo-upgrades-continue-16-06-2023
This article was researched and written with AI assistance, using court filings, public records, and news sources. AI-generated content can contain errors. Verify all information against primary sources before relying on it. This is not legal or financial advice. See the disclaimer.